Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 5, 2006, Pages 442-450

  Otová, Berta ^a   Václavíková, Radka ^b   Danielová, Vlasta ^b   Holubová, Jaroslava ^b   Ehrlichová, Marie ^c   Horský, Stanislav ^b   Souček, Pavel ^b   Šimek, Petr ^d   Gut, Ivan ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^d INSTITUTE OF ENTOMOLOGY   (Czech Republic)

Author keywords

Anticancer; Bioavailability; Docetaxel; Efficiency; Metabolism; P glycoprotein; Paclitaxel

Indexed keywords

CYTOCHROME P450; DOCETAXEL; GLYCOPROTEIN P; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL TIME; T CELL LYMPHOMA; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HUMANS; INTESTINES; LYMPHOMA, T-CELL; MICE; MICROSOMES, LIVER; P-GLYCOPROTEIN; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; SUBCUTANEOUS TISSUE; TAXOIDS;

EID: 33750696646     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.08.007     Document Type: Article

References (32)

1. Anderson C.D., Wang J., Kumar G.N., McMillan J.M., Walle U.K., and Walle T. Dexamethasone induction of taxol metabolism in the rat. Drug Metabol. Dispos. 23 (1995) 1286-1290
2. Bobková K., Gut I., Mandys V., Holý A., Votruba I., and Otová B. Antitumor activity of combined treatment with PMEDAP and docetaxel in the Prague inbred Sprague-Dawley/cub rat strain bearing T-cell lymphoma. Anticancer Res. 21 (2001) 2725-2732
3. Budman D.R., Petroni G.R., Johnson J.L., Cooper M.R., Schlossman D.M., Barcos M., and Peterson B.A. Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B. J. Clin. Oncol. 15 10 (1997) 3275-3279
4. Dimopoulos M.A., Arbuck S., Huber M., Weber D., Luckett R., Delasalle K., and Alexanian R. Primary therapy of multiple myeloma with paclitaxel. Ann. Oncol. 5 (1994) 757-759
5. Dorr R.T. Pharmacology of the taxanes. Pharmacotherapy 17 5 Pt 2 (1997) 96S-104S
6. Ehrlichová M., Václavíkova R., Ojima I., Wu X., Kuznetsova L.V., Chen J., Truksa J., Soucek P., Kovar J., and Gut I. Transport and cytotoxicity of paclitaxel, docetaxel and three novel taxanes in human breast cancer cells. N-S Arch. Pharmacol. 372 (2005) 95-105
7. Ehrlichová M., Koc M., Truksa J., Naldova Z., Vaclavikova R., and Kovar J. Cell death induced by taxanes in breast cancer cells: cytochrome c is released in resistant but not in sensitive cells. Anticancer Res. 25 (2005) 4215-4224
8. Escobar P.F., and Rose P.G. Docetaxel in ovarian cancer. Expert Opin. Pharmacother. 15 (2005) 2719-2726
9. Fan W. Possible mechanisms of paclitaxel-induced apoptosis. Biochem. Pharmacol. 57 (1999) 1215-1221
10. Gut I., Danielová V., Holubová J., Souček P., and Klučková H. Cytotoxicity of cyclophosphamide, paclitaxel and docetaxel for tumor cell lines in vitro: effects of concentration, time and CYP-catalyzed metabolism. Arch. Toxicol. 74 (2000) 437-446
11. Gut I., Terelius Y., Frantík E., Linhart I., Souček P., Filipcová B., and Klučková H. Exposure to various benzene derivatives differently induces cytochromes P450 2B1 and 2E1 in the rat liver. Arch. Toxicol. 67 (1993) 237-243
12. Harris J.W., Katki A., Anderson L.W., Chmurny G.N., Paukstelis J.V., and Collins J.M. Isolation, structural determination, and biological activity 6α-hydroxytaxol, the principal human metabolite of taxol. J. Med. Chem. 37 (1994) 706-709
13. Huang L., Wring S.A., Woolley J.L., Brouwer K.R., Serabjit-Singh C., and Polli J.W. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metabol. Dispos. 29 (2001) 754-760
14. Huizing M.T., Sewberath Misser V.H., Pieters R.C., ten Bokkel Huinink W.W., Veenhof C.H.N., Vermorken J.B., Pinedo H.M., and Beijnen J.H. Taxanes: a new class of antitumor agents. Cancer Invest. 13 (1995) 381-404
15. Lin C.M., Jiang Y.Q., Chaudhary A.G., Rimoldi J.M., Kingston D.G., and Hamel E. A convenient tubulin-based quantitative assay for paclitaxel (Taxol) derivatives more effective in inducing assembly than the parent compound. 20. Cancer Chemother. Pharmacol. 38 2 (1996) 136-140
16. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
17. Monsarrat B., Royer I., Wright M., and Cresteil T. Biotransformation of taxoids by human cytochromes P450: structure-activity relationship. Bull. Cancer 84 (1997) 125-133
18. Ohnishi K., and Ohno R. New antitumor drugs for non-Hodgkin's lymphoma. Gan To Kagaku Ryoho. 25 14 (1998) 2223-2228 [in Japanese]
19. Otová B., Sladká M., Damoiseaux J., Panczak A., Mandys V., and Marinov I. Relevant animal model of human lymphoblastic leukaemia/lymphoma - spontaneous T-cell lymphomas in an inbred Sprague-Dawley rat strain (SD/Cub) - Review. Folia Biologica (Praha) 48 (2002) 213-226
20. Rowinsky E.K., Onetto N., Canetta R.M., and Arbuck S.G. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19 (1992) 646-662
21. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 22 (1979) 665-667
22. Schimming R., Mason K.A., Hunter N., Weil M., Kishi K., and Milas L. Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel. Cancer Chemother. Pharmacol. 43 2 (1999) 165-172
23. Shou M., Martinet M., Korzekwa K.R., Krausz K.W., Gonzales F.J., and Gelboin H.V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives; enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 8 (1998) 391-401
24. Spencer M.C., and Faulds D. Paclitaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48 (1994) 795-845
25. Vaclavikova R., Horsky S., Simek P., and Gut I. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch. Pharmacol. 368 (2003) 200-209
26. Vaclavikova R., Soucek P., Svobodova L., Anzenbacher P., Simek P., Guengerich F.P., and Gut I. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, minipigs and regular pigs. Drug Metabol. Dispos. 32 (2004) 666-674
27. Walle T., Kumar G.N., McMillan J.M., Thornburg K.R., and Walle U.K. Taxol metabolism in rat hepatocytes. Biochem. Pharmacol. 46 (1993) 1661-1664
28. Younes A., Ayoub J.P., Sarris A., North L., Pate O., McLaughlin P., Rodriguez M.A., Romaguera J., Hagemeister F., Bachier C., Preti A., and Cabanillas F. Paclitaxel (Taxol) for the treatment of lymphoma. Ann. Oncol. 8 Suppl. 1 (1997) 129-131
29. Younes A., Cabanillas F., McLaughlin P.W., Hagemeister F.B., Farber C., Sarris A., Pate O., Myers J., and Portlock C. Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease. Ann. Oncol. 7 10 (1996) 1083-1085
30. Younes A., Sarris A., Melnyk A., Romaguera J., McLaughlin P., Swan F., Rodriguez M.A., Hagemeister F., Moore D., et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 13 3 (1995) 583-587
31. Zekri J.M., Hough R.E., Davies J.M., Molife R., Hancock B.W., and Lorigan P.C. Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma. Br. J. Cancer 88 9 (2003) 1335-1338
32. Zhu K., Gerbino E., Beaupre D.M., Mackley P.A., Muro-Cacho C., Beam C., Hamilton A.D., Lichtenheld M.G., Kerr W.G., Dalton W., Alsina M., and Sebti S.M. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 105 12 (2005) 4759-4766